Skip to content Skip to sidebar Skip to footer
Subscribe Now
Bruno Vision Care
News

Bruno Vision Care’s Deseyne Contact Lens Secures the US FDA’s Approval for Dry Eye Disease

Shots: The US FDA has approved Deseyne (vifilcon C) daily disposable contact lens with FusionTechnology; commercially available in Q4’25 Deseyne lenses integrates 2 patented innovations: vifilcon C hydrogel material & FusionTechnology, to gradually release embedded Lachryceuticals (incl. amino acids, vitamins, & polysaccharides), ensuring sustained bioavailability & long-lasting eye comfort FusionTechnology combines hyaluronic acid & tamarind…
April 15, 20250Comments

Read more

Cue Biopharma & Boehringer Ingelheim
News

Cue Biopharma Collaborates with Boehringer Ingelheim to Develop B cell-Targeting Bispecifics for Autoimmune and Inflammatory Diseases

Shots: BI & Cue Biopharma have entered into a multi-year strategic research & license agreement to develop & commercialize CUE-501 for autoimmune diseases, with the potential to expand into other B cell-targeting bispecifics using Cue’s Immuno-STAT platform As per the deal, Cue Biopharma will receive a $12M upfront & ~$345M in research, development, & commercial…
April 15, 20250Comments

Read more

Intas & Coherus
News

Intas Pharmaceuticals Acquires Coherus BioSciences’ Udenyca Business (Biosimilar, Neulasta)

Shots: Intas has acquired Coherus’ Udenyca business (incl. prefilled syringe, autoinjector & on-body injector), a biosimilar version of Amgen’s Neulasta (pegfilgrastim) via 2024 asset purchase agreement; Accord BioPharma (Intas’ US specialty division) will handle Udenyca’s US business As per the deal, Coherus received $483.4M upfront in cash, incl. $118.4M for Udenyca inventory, with an additional…
April 15, 20250Comments

Read more

Pfizer
News

Pfizer to Discontinue Danuglipron’s Development Program for Chronic Weight Management

Shots: Pfizer has discontinued the development of danuglipron (PF-06882961) as a potential therapy for chronic weight management Danuglipron was evaluated in 2 P-I trials (NCT06567327 & NCT06568731), meeting key PK objectives & confirming formulation & dose with potential for strong efficacy & tolerability in P-III. However, a case of drug-induced liver injury & recent regulatory input led…
April 14, 20250Comments

Read more

Spotlight Interview_Ali Jannati
SPOTLIGHT

CXO Talks: Ali Jannati from Linus Health in a Stimulating Dialogue Exchange with PharmaShots

In the CXO Talks podcast, PharmaShots spoke with Ali Jannati, Director of Cognitive Science at Linus Health. Ali eloquently highlighted Linus’ journey to becoming a leader in digital brain health through its innovative digital cognitive assessment platform He emphasized the importance of digital biomarkers in evaluating brain function by capturing subtle nuances and response latencies,…
April 14, 20250Comments

Read more

Chromatin Bioscience & Astellas
News

Astellas Collaborates with Chromatin Bioscience to Develop Cell-Selective Synthetic Promoters

Shots: Astellas has entered into a collaboration agreement with Chromatin Bioscience to design cell-selective synthetic promoters As per the agreement, Chromatin will utilize its chromatinLENS platform to develop cell-selective synthetic promoters for Astellas’ target profile, allowing precise & durable gene expression in specific cells chromatinLENS platform identifies gene regulatory elements from the dark genome &…
April 14, 20250Comments

Read more

Roche
News

Roche’s Columvi (Glofitamab) Regimen Receives the EC’s Approval to Treat R/R Diffuse Large B-Cell Lymphoma (DLBCL)

Shots: The EC has granted full approval to Columvi + GemOx for ASCT-ineligible r/r DLBCL pts based on P-III (STARGLO) trial assessing the regimen vs MabThera/Rituxan + GemOx in previously treated DLBCL pts At 11.3mos. mFU (primary analysis), trial showed improved OS, a 41% reduction in death risk, with a 63% improvement in PFS. At…
April 14, 20250Comments

Read more

Innoblative
News

Innoblative Secures the US FDA’s IDE Approval of SIRA Electrosurgical Device for Breast Cancer Patients

Shots: The US FDA has granted IDE approval to initiate US feasibility study of SIRA radiofrequency ablation (RFA) electrosurgical device for pts undergoing breast-conservation surgery (BCS) SIRA device is a single-use applicator designed to deliver circumferential RFA to the post-lumpectomy cavity during breast-conserving surgery to provide consistent ablation depth & increased confidence in margin treatment…
April 14, 20250Comments

Read more

Sign Up to Our Newsletter

Be the first to know the latest updates

[mc4wp_form id="13387" element_id="style-1"]